Area of research
Genetics · Pulmonary and Respiratory Medicine
Research interest
Research interests include Medicine, Internal medicine, Oncology, Glioma, Cerebrospinal fluid, and Cancer.
Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions
Leptomeningeal metastatic disease: new frontiers and future directions
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 <scp>U.S.</scp> cancer centers
Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.
Abstract CT224: Multi-institutional randomized phase-3 trial comparing cancer stem cell-targeted vs physician-choice treatments in patients with recurrent high-grade gliomas (NCT03632135)
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications
Management of low-grade glioma: a systematic review and meta-analysis
External ventricular drain practice variations: results from a nationwide survey
Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase
A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.
AT-60 * A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) VACCINE ICT-107 FOLLOWING STANDARD TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH GBM
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme